ECM
PRTK

ExodusPoint Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

ExodusPoint Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,852
Closed -$33K – 2432
2022
Q2 		$33K Buy
+16,852
New +$36.8K ﹤0.01% 1828
2021
Q3 		– Sell
-54,728
Closed -$373K – 2814
2021
Q2 		$373K Buy
+54,728
New +$442K ﹤0.01% 1604

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

ExodusPoint Capital Management's PRTK Position: Q3 2022 in Review

ExodusPoint Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2022, closing a stake of 16,852 shares — an estimated $33K sold.

ExodusPoint Capital Management first reported a position in PRTK in Q2 2021 and held it in 2 quarters. The position peaked at $373K in Q2 2021. 72 funds tracked by Wall St. Rank hold PRTK as of Q3 2022.

  • ExodusPoint Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 16,852 Paratek Pharmaceuticals, Inc. shares in Q3 2022, an estimated $33K.
  • ExodusPoint Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
  • ExodusPoint Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $373K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2022.

Based on ExodusPoint Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.